Merus Presents Clinical Data On Zenocutuzumab In NRG1-fusion (NRG1+) Cancers At 2021 ASCO Meeting
Merus N.V. (NASDAQ:MRUS) ("Merus", "the Company", "we", or "our"), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and